Phase 2 baseline-controlled clinical trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Vascular malformations
- Focus Therapeutic Use
- 15 Oct 2024 New trial record